Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Disclaimer - Peptide Dosages

Last updated: August 13, 2025 The information provided on DosagePeptide (dosagepeptide.com) is for educational and informational purposes only. We do not sell products and we do not provide medical advice, diagnosis, treatment, or prescriptions. All content is

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Last updated: August 13, 2025

The information provided on DosagePeptide (dosagepeptide.com) is for educational and informational purposes only. We do not sell products and we do not provide medical advice, diagnosis, treatment, or prescriptions. All content is intended for research, academic, or general knowledge use.

1. Not medical advice

Content on this site, including dosage protocols, reconstitution details, and other peptide information, should not be interpreted as medical guidance. Always seek the advice of a qualified healthcare professional before making decisions related to your health, medical conditions, or treatment plans.

2. Research use only

Any protocols, measurements, or instructions described are based on publicly available research data or general knowledge in the field. They are intended solely for research and educational reference, not for human or veterinary therapeutic use.

3. No guarantees

While we strive for accuracy and up-to-date information, we make no guarantees regarding the completeness, accuracy, reliability, or applicability of any content. You use the information provided on this site at your own risk.

4. External links

This website may contain links to third-party websites for reference or convenience. We do not control, endorse, or take responsibility for the content, policies, or practices of these external sites.

5. Liability

If you have questions about this disclaimer, please contact us at:[email protected]

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01P21 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. P21 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Thymogen — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Thymogen is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

The Mechanism That Frames Every Research Question

Every legitimate research question about Sermorelin ultimately traces back to its mechanism, so it is worth laying that out precisely. Sermorelin binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed predominantly on the somatotroph cells of the anterior pituitary. Receptor engagement activates the stimulatory Gs protein, which stimulates adenylyl cyclase, raising intracellular cyclic AMP. The rise in cAMP activates protein kinase A, which both promotes the immediate release of stored growth hormone and, through downstream transcription factors such as CREB and the pituitary-specific factor Pit-1, drives transcription of the GH gene and supports somatotroph proliferation.6 In short, Sermorelin does not supply growth hormone; it instructs the pituitary to make and release its own. The mechanics of that pituitary-level signaling are explored further in the site’s discussion of how Sermorelin affects pituitary signaling in endocrine research. Two features of this mechanism generate most of the compound’s theoretical appeal, and both deserve careful, non-inflated treatment. The first is preservation of feedback. Growth-hormone secretion is restrained by somatostatin, the hypothalamic “off” signal, and by IGF-1-mediated negative feedback. Because Sermorelin acts upstream at the pituitary rather than flooding the body with exogenous hormone, its output remains subject to these brakes. The practical implication, argued in the clinical literature, is that it is difficult to drive endogenous GH to grossly supraphysiological levels with a GHRH stimulus alone, because somatostatin tone rises to oppose it.4 This is a genuine and attractive property in principle — it is the mechanistic basis for the claim that GHRH-based approaches are “self-limiting” in a way that injected recombinant GH is not. The second is pulsatility. Physiological GH secretion is episodic, occurring in discrete pulses (especially during slow-wave sleep) against a low baseline. This pulsatile pattern is not incidental; the biological effects of GH depend partly on the pattern of exposure, not merely the total amount. A GHRH stimulus, working through the intact pituitary, tends to produce release that is more episodic than the flat, non-physiological profile of a recombinant GH injection.4 Restoring a more natural secretory rhythm, rather than simply raising the average, is one of the more scientifically interesting propositions attached to the compound. Here honesty requires a firm caveat. These are compelling mechanistic rationales, and they are frequently presented as though they were demonstrated clinical outcomes. They are not the same thing. That a GHRH analog preserves feedback and encourages pulsatility is a reasonable pharmacological expectation; that this translates into meaningful, durable benefit for body composition, sleep, recovery, or aging in otherwise-healthy adults is a separate empirical question that Sermorelin’s own evidence base does not robustly answer. The mechanism is the source of the hypotheses, not the confirmation of them. And the short half-life re-enters here: a molecule cleared within roughly ten to twelve minutes must be dosed to catch the physiological windows in which it can actually shape a pulse, which is why the timing conventions around it exist and why sustained effects cannot be assumed from a transient signal.3

Source: dosagepeptide.com ↗

Limitations and the Human-Evidence Gap

Every honest account of NAD+ and Parkinson’s disease converges on the same conclusion: the human evidence gap is wide, and the most important results are not yet in. It is worth cataloguing the specific limitations, because they are what separate a promising research program from a proven therapy, and because they are exactly the details that hype tends to omit. The first limitation is trial size and duration. The two completed randomized trials in Parkinson’s disease enrolled 30 and 20 participants and lasted 30 days and 4 weeks respectively.1,2 These are appropriate designs for their stated purposes, safety and target engagement, but they are structurally incapable of demonstrating disease modification, which manifests as a gradual divergence of progression curves over a year or more. Any clinical improvement seen in such short trials is more likely to reflect symptomatic effects, measurement variability, or confounding than a change in the underlying neurodegenerative process. The NR-SAFE authors’ own caution about levodopa-timing confounding their UPDRS signal is a model of the appropriate humility.2 The second limitation is the responder problem. NADPARK showed that oral NR raises brain NAD+ in some participants but not others, and that clinical and metabolic signals clustered in the responder subgroup.1 This heterogeneity is scientifically important but clinically double-edged: it means that even if NAD+ elevation helps, an intention-to-treat analysis that includes non-responders may dilute the effect below detectability, while a responder-only analysis risks the statistical pitfalls of post-hoc subgrouping. Sorting out who responds, why, and how to identify them in advance is unfinished work. The third limitation is the model-to-human translation gap already discussed. The mechanistic and preclinical case is strong, but Parkinson’s disease has an unusually long history of interventions that protected neurons in animals and then failed in rigorous human trials, from antioxidants to anti-apoptotic agents to other mitochondrial strategies. NAD+ boosting could be different, but the base rate argues for caution until the phase III data are published.1,5 The fourth limitation concerns the epidemiology: the cross-sectional NHANES analysis linking higher dietary niacin intake to lower Parkinson’s prevalence is consistent with the hypothesis but cannot establish causation, and the larger EPIC-based cohort study examined niacin and tryptophan intake against incident Parkinson’s disease without providing the kind of confirmed protective association that would strengthen the causal case.10,11 Observational designs of this type are in any event particularly vulnerable to reverse causation, because prodromal Parkinson’s disease alters diet, smell, appetite, and gastrointestinal function years before diagnosis. The fifth limitation is conceptual: “NAD+ deficiency” is not a single, cleanly measured, universally agreed entity in Parkinson’s disease. Different studies measure NAD+ in different tissues (brain, cerebrospinal fluid, blood, skeletal muscle) using different techniques, and these compartments do not move in lockstep. The finding of lower NAD+ or lower NAD+-synthesizing enzymes in some Parkinson’s tissues is real and reproducible in places, but whether it is a primary driver of neurodegeneration, a downstream consequence of mitochondrial failure, or both at once is not resolved.4,6 A therapy premised on correcting a deficiency needs a clear picture of what deficiency it is correcting and where. Until the NOPARK results and comparable trials are published and, ideally, independently replicated, the responsible bottom line is that NAD+ precursors remain an unproven, investigational approach in Parkinson’s disease, however biologically attractive the rationale.3

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

Chonluten (20mg Vial) Dosage Protocol

Khavinson lung/bronchial short-peptide bioregulator (EDG) — research-only; not approved, benefits unproven.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →